It’s been a productive time behind the scenes, and we’re eager to share what we’ve been up to! 💥
We’re proud to announce 6 new investments in groundbreaking science-based spinouts! At NSI, we’re committed to fueling #deeptech innovation in the New Nordics through strong collaboration with universities. 🤝
Welcome to the NSI portfolio:
Kasvu Therapeutics
early-stage drug development company founded in 2023. Building on a breakthrough discovery by its founders at the University of Helsinki, the company has developed novel rapid acting neuroplastogens for the treatment of various mental, behavioral and neurodevelopmental disorders, such as depression.
AIATELLA
transforms cardiovascular diagnostics by harnessing AI to automate quantification, detection, and interpretation of medical images across multiple imaging modalities. Their technology boosts efficiency, ensures standardized analysis, and enables precision medicine, addressing the global challenges of radiologist shortages and the rising burden of cardiovascular diseases.
NextInox
develops and commercializes new stainless steel technologies to enhance the performance level of existing grades and to create new ones for the future. Applications for these materials range from household products to high-end technical solutions and provide value through the whole supply chain and product life cycle in a sustainable manner.
NADMED Ltd.
a spinout from the University of Helsinki, has revolutionized the measurement of NADs, vital molecules that act as the energy readout of cells. These molecules are linked to several diseases, including heart disease, metabolic disorders, and cancer. With the only CE-marked medical device for NAD measurement, NADMED offers the most advanced and accurate method available.
Thestra
A spinout from over a decade of research at Turku University and Turku University Hospital, THESTRA specializes in cancer diagnostics. With its patented EPLINEx™ technology, the company brings groundbreaking solutions to market, uniquely identifying life-threatening head and neck cancer cases where diagnostic options are lacking. THESTRA focuses on enabling personalized cancer medicine through precise patient-specific diagnostics and therapy stratification solutions.
RNatives
a spinout from the University of Eastern Finland, is leading the way in the exciting field of microRNA (miRNA) technology. They use unique, patented nuclear miRNAs to control how specific genes behave, opening new doors for treating complex diseases. Their platform, which will soon integrate AI for even more accuracy, has the potential to change how we approach and treat a wide range of health conditions.
#DeepTech #Innovation #ResearchCommercialization